To investigate the effect of preoperative uses of levosimendan in patients with low LVEF(≤0.40) undergoing off-pump coronary artery bypass grafting(OPCABG).

63 patients with low LVEF coronary artery diseases were prospectively enrolled during June 2015 to May 2018, randomized to levosimendan-treated group(n=32) and control group(n=31)preoperatively. Patients in levosimendan-treated group underwent levosimendan intravenous infusion 24 h before OPCABG. All patients underwent OPCABG at normal temperature. Internal mammary artery and great saphenous vein were used as bypass materials. Hemodynamics and cardiac function were compared between the two groups after OPCABG.

Compared to control group, the systemic vascular resistance(SVR) and central venous pressure(CVP) of levosimendan-treated group were decreased significantly and the CO and LVEF increased significantly at 12h and 24h after surgery(P<0.05). The heart rate and mean artery pressure had no statistical difference between the two groups(P>0.05). The dosage and administration time of vasoactive agents in levosimendan-treated group were significantly smaller than those in control group(P<0.05). The time of mechanical ventilation, the ICU stay length, the BNP level in the first two days after operation, and the incidence of new atrial fibrillation were less than those of the control group(P<0.05). The perioperative intra-aortic balloon pump implantation rate in levosimendan-treated group was significantly lower than that of the control group(P<0.05).

Preoperative use of levosimendan can significantly improve the hemodynamic and cardiac function status of patients with low LVEF after OPCABG, shorten the time of ventilator assisted and ICU hospitalization, and reduce the incidence of adverse events.

Off-pump coronary artery bypass grafting; Preoperative; Levosimendan; Hemodynamic; Cardiac function